SCHEMBL1472014

SCHEMBL1472014

CCc1nc2c(c(C)nn2C)c(Cl)c1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 12/20 0.39
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
S1PR2 O95136 2/20 0.38
MAPT P10636 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NOTUM Q6P988 1/20 0.36
MAPK1 P28482 1/20 0.36
CLK1 P49759 1/20 0.36
UBE2N P61088 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7005066 0.80 HPGD (0.54) NR3C1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL4930739 0.76 KMT2A (0.34) NR3C1KDM4EALDH1A1HPGDMAPT
SCHEMBL12604362 0.71 KMT2A (0.49) NR3C1KDM4EALDH1A1HPGD
SCHEMBL6289424 0.70 SMN1; SMN2 (0.44) KDM4EALDH1A1HPGD
SCHEMBL4930821 0.69 NPC1 (0.32) NR3C1
SCHEMBL8832465 0.68 NR3C1 (0.33) NR3C1KDM4EALDH1A1
SCHEMBL21713101 0.67 FABP3 (0.40) KDM4EALDH1A1HPGDMAPTMAPK1
SCHEMBL8304267 0.67 L3MBTL1 (0.44) NR3C1KDM4EALDH1A1MAPTL3MBTL1
SCHEMBL14752623 0.67 S1PR2 (0.47) NR3C1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2639271 0.67 NR3C1 (0.62) NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915286-B2 Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2011-03-29 US disclosed
US-20100022571-A1 SUBSTITUTED PYRAZOLO [3,4-B]PYRIDINES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-01-28 US disclosed
US-20090306129-A1 SUBSTITUTED PYRAZOLO [3,4-B] PYRIDINES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022571-A1 SUBSTITUTED PYRAZOLO [3,4-B]PYRIDINES AS PHOSPHODIESTERASE INHIBITORS PDE4B, PDE4A, PDE3B NR3C1 3791/4885KDM4E 282/4885ALDH1A1 1198/4885
US-20090306129-A1 SUBSTITUTED PYRAZOLO [3,4-B] PYRIDINES AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE4B, PDE3A NR3C1 3658/4885KDM4E 281/4885ALDH1A1 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.